Epilepsy - Global Clinical Trial Landscape (2024)

Around one third of individuals with the disease are drug-resistant, highlighting a significant need for innovative therapies to address this and the disease as a whole. Biomarkers and precision therapies show encouraging results, but there is still work to be done. In this latest report by Novotech, gain comprehensive insight on:

Current treatment and management of epilepsy
Statistics on the global clinical trial and drug discovery landscape
Insight into public vs venture capital funding
Innovative therapies showing promise
Impact of telemedicine and digital health tech on patient care

Read the Report

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Novotech to store and process the information submitted to provide you the content requested. They are subject to Novotech’s Terms and Conditions.

Epilepsy - Global Clinical Trial Landscape (2024)

Read the Report

Opt In?

Explore similar content

Safety & Regulatory Compliance Predictions For 2025

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Getting The Most Out Of Your Lab Space